Fumarate propafenone tablets (Vemlidy) are nucleoside analogue reverse transcriptase inhibitors (NRTI) that inhibit the reverse transcriptase activity of hepatitis B virus (HBV), block the extension of viral DNA strands, and thus inhibit viral replication.

1、 Drug name

1. Common name: Propionine Fumarate Tenofovir Tablets

2. Product Name: Vemlidy ®

3. English name: Tenofovir Alafenamide Fumarate Tablets

2、 Indications

Vemlidy is suitable for treating chronic hepatitis B virus (HBV) infection in adults, and patients must have compensatory liver disease.

3、 Specifications and characteristics

Each tablet contains 25mg of propafenone (equivalent to 28mg of propafenone fumarate).

4、 Main components

1. Active ingredient: Tenofovir Alafenamide

2. Accessories: cross-linked carboxymethyl cellulose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose. The film coating contains iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc powder, and titanium dioxide.

5、 Usage and dosage

The recommended dosage is once daily, one tablet (25mg) each time, to be taken with meals.

6、 Dose adjustment

1. Patients with renal insufficiency: Mild to severe renal insufficiency (creatinine clearance rate ≥ 15mL/min) do not require dose adjustment; End stage renal disease (creatinine clearance rate<15mL/min) is not recommended for use.

2. Patients with liver dysfunction: Mild liver injury (Child Pugh A grade) does not require dose adjustment; Not recommended for decompensated liver disease (Child Pugh B or C grade).

7、 Medication precautions

1. Medication time: It should be taken with meals to improve absorption.

2. Omission: It should be avoided as much as possible. If missed, it should be taken as soon as possible when remembered, but if it is close to the next dose, the missed dose should be skipped and double the dose should not be taken.

3. Vomiting: If vomiting occurs after taking medication, there is no need to take it again. Follow the original plan for the next dose.

8、 Medication for special populations

1. Pregnant women: There is no human data available, and animal experiments have not shown teratogenicity. It is recommended to participate in antiviral pregnancy registration during use.

2. Breastfeeding period: It is not yet clear whether it is secreted into human milk, and the decision to breastfeed should be made after weighing the pros and cons.

3. Children: Safety and efficacy data for patients under 18 years old have not been established.

4. Elderly individuals: Data is limited, it is recommended to use personalized medication based on kidney function.

9、 Adverse reactions

1. Common adverse reactions (incidence ≥ 5%) include headache, abdominal pain, fatigue, cough, nausea, and back pain.

2. Serious adverse reactions include: lactic acidosis/hepatic steatosis, worsening of hepatitis, renal dysfunction, etc.

10、 Contraindications

There are no clear contraindications.

11、 Drug interactions

1. Vemlidy is a substrate for P-glycoprotein (P-gp) and BCRP. When used in combination with potent inducers such as carbamazepine, rifampicin, and St. John's wort, it may reduce its blood drug concentration and should be avoided or the dosage adjusted.

2. When used in combination with drugs that are excreted through the kidneys or have nephrotoxicity, such as acyclovir and NSAIDs, renal function should be monitored.

12、 Storage method

Store at a temperature not exceeding 30 ° C (86 ° F), keep the container sealed, and only distribute in its original packaging.

Vemlidyinformation